Virbac SA (VIRP.PA)

Executive Summary

Virbac SA is a leading independent animal health company globally, with a diversified portfolio spanning pharmaceuticals, vaccines, and nutritional solutions for both companion animals and livestock. Founded in 1968 and headquartered in Carros, France, the company operates in over 100 countries and has a market capitalization of approximately $3.3 billion. Virbac's strategy focuses on innovation, geographic expansion, and strategic acquisitions to strengthen its product offerings. The company has demonstrated consistent revenue growth, driven by strong demand in the companion animal segment and expansion in emerging markets. Its R&D pipeline includes several promising vaccine and therapeutic candidates targeting unmet needs in veterinary medicine.

Upcoming Catalysts (preview)

• Q4 2026FDA approval of novel canine leishmaniasis vaccine70% success
• Q2 2026Acquisition of a niche animal health biotechnology company60% success
• Q3 2026Launch of new livestock nutritional supplement in Asia-Pacific markets80% success